Tvardi Therapeutics is trading at $1.04, down 5.00%, as broader market and biotech weakness may be weighing on shares.
- No October 8 company-specific announcement appears in Tvardi Therapeutics’ press-release listings; the latest listed release is dated September 24.
- Biotech is down 2.04%, while geopolitical tensions and rising oil prices are pressuring markets.
- Supplied price context shows the stock also closed lower on October 6 and October 2, indicating recent weakness.